Literature DB >> 11981460

Failure of Helicobacter pylori eradication: is poor compliance the main cause?

Joël Wermeille1, Michael Cunningham, Jean-Pierre Dederding, Laurent Girard, Rémy Baumann, Georges Zelger, Pierre Buri, Jean-Michel Metry, Radan Sitavanc, Landri Gallaz, Hans Merki, Norman Godin.   

Abstract

OBJECTIVE: The aim of the study was to evaluate whether poor compliance can be considered as the main cause of the low Helicobacter pylori (H. pylori) eradication rate observed in an ambulatory population.
METHODS: Seventy-eight patients with non-ulcer dyspepsia or gastroduodenal ulcer in whom H. pylori infection was confirmed by urease Clo-test and histology or bacterial culture, received a 1-week triple therapy comprising lansoprazole 30 mg b.d., amoxicillin 1000 mg b.d. and clarithromycin 500 mg b.d. Compliance was assessed using MEMS(R) containers (Medication Event Monitoring System) which recorded time of medicines consumption.
RESULTS: The overall H. pylori eradication rate was 65.4% (95% CI: 54.8-76.0%) (intention to treat). Sixty-nine subjects (88.5%) consumed greater than 85% of doses and were considered as "good compliers". The major reason listed by the nine remaining patients for stopping treatment prematurely was side effects. In the population categorised as "good compliers", H. pylori eradication rate was 69.6% (95% CI: 58.7-80.5%) (per protocol) indicating that compliance could not be considered as the sole reason for treatment failure. Bacterial culture in a subset of 30 patients further showed a H. pylori eradication rate of 73.9% (95% CI: 55.7-92.1%) in "good compliers" with a clarithromycin-sensitive H. pylori strain. On multivariate analysis, H. pylori eradication was inversely associated with poor compliance (P=0.029). Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups.
CONCLUSION: Although poor compliance and bacterial resistance were important factors in determining treatment success in our population, they could only explain 40% of failures suggesting that other factors must be involved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981460

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  15 in total

1.  A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan.

Authors:  Toshio Fujioka; Nobuo Aoyama; Kyoko Sakai; Yoshiyuki Miwa; Mineo Kudo; Junichi Kawashima; Yasuo Matsubara; Jun Miwa; Koji Yakabi
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

2.  Update on Therapeutic Options for Helicobacter pylori-related Diseases.

Authors:  Francis Mégraud
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

3.  Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients.

Authors:  Won-Chul Chang; Young-Il Jo; Hyung-Seok Park; Joon Jegal; Jung-Hwan Park; Jong-Ho Lee; Choon-Jo Jin
Journal:  Clin Exp Nephrol       Date:  2010-07-15       Impact factor: 2.801

Review 4.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

Review 5.  High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.

Authors:  Mei Zhang
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

6.  Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

Authors:  Intetsu Kobayashi; Kazunari Murakami; Mototsugu Kato; Seiichi Kato; Takeshi Azuma; Shin'ichi Takahashi; Naomi Uemura; Tsutomu Katsuyama; Yoshihiro Fukuda; Ken Haruma; Masaru Nasu; Toshio Fujioka
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

Review 7.  Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.

Authors:  Francis Mégraud
Journal:  Gut Microbes       Date:  2013-08-05

8.  Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.

Authors:  Yue-Feng Tong; Jun Lv; Li-Yuan Ying; Fang Xu; Bo Qin; Ming-Tong Chen; Fei Meng; Miao-Ying Tu; Ning-Min Yang; You-Ming Li; Jian-Zhong Zhang
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

9.  Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.

Authors:  Jie Pan; Zhengchao Shi; Dingsai Lin; Ningmin Yang; Fei Meng; Lang Lin; Zhencheng Jin; Qingjie Zhou; Jiansheng Wu; Jianzhong Zhang; Youming Li
Journal:  Front Med       Date:  2020-01-03       Impact factor: 4.592

Review 10.  Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens.

Authors:  Shen-Shong Chang; Hsiao-Yun Hu
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.